[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Advisory Board
Aims & Scope
Journal News
Articles archive::
All Issues
Current Issue
Articles in press
For Authors::
Submission Instruction
For Reviewers::
Reviewers Section
Subscription::
Subscription Form
News& Events::
Journal News
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
Top 10 contents
Inform others
Ethics & Permissions::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 15, Issue 3 (Autumn 2018) ::
Sci J Iran Blood Transfus Organ 2018, 15(3): 226-234 Back to browse issues page
The evaluation of P16 in chronic myeloid leukemia patients
Mina Barazandeh-Rokh , Nikoo Nasoohi , Mojtaba Molaei , Parviz Fallah
Keywords: Key words: Myeloid Leukemia, Chronic, PCR, Hematopoietic Stem Cells
Full-Text [PDF 439 kb]   (1773 Downloads)     |   Abstract (HTML)  (4424 Views)
Type of Study: Research | Subject: Hematology and Oncology
Published: 2018/12/4
Full-Text:   (2628 Views)
References:
  1. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 2011; 117(6): 1113-22.
  2. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66(4): 271-89.
  3. Warsch W, Walz C, Sexl V. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 2013; 122(13): 2167-75.
  4. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 2011; 25(3): 463-72.
  5. Carrasco Salas P, Fernández L, Vela M, Bueno D, González B, Valentín J, et al. The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol 2016; 33(7-8): 415-22.
  6. Cividin M, Ayrault O, Sorel N, Séité P, Brizard F, Blanchet O, et al. Expression of the cell cycle regulators p14ARF and p16INK4a in chronic myeloid leukemia. Leuk Res 2006; 30(10): 1273-8.
  7. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39(3): 347-51.
  8. Imtiyaz A, Rashid M, Sameer G, Jamsheed J, Mariyam Z. Inactivation of P16 (INK4a) Gene by Promoter Hypermethylation is Associated with Disease Progression in Chronic Myelogenous Leukaemia. J Carcinogene Mutagene 2013; 4: 141.
 
 
 
 
  1. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264(1): 42-55.
  2. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12(6): 845-59.
  3. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1(1): 75-87.
  4. Lee YK, Park JY, Kang HJ, Cho HC. Overexpression of p16INK4A and p14ARF in haematological malignancies. Int J Lab Hematol 2003; 25(4): 233-7.
  5. Nasif KA, El-Gezawy EM, Sedeek OB, Aly SM. Concomitant Overexpression of P16 INK 4 A and P14 ARF in Chronic Myeloid Leukaemia. Med J Cairo Univ 2009; 77(4): 143-50.
  6. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002; 21(21): 3475-95.
  7. Taniguchi T, Chikatsu N, Takahashi S, Fujita A, Uchimaru K, Asano S, et al. Expression of p16 INK4A and p14 ARF in hematological malignancies. Leukemia 1999; 13(11): 1760-9.
  8. Dai C, Krantz SB. Increased expression of the INK4a/ARF locus in polycythemia vera. Blood 2001; 97(11): 3424-32.
  9. Zindy F, Quelle DE, Roussel MF, Sherr CJ. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997; 15(2): 203-11.
  10. Ressler S, Bartkova J, Niederegger H, Bartek J, Scharffetter-Kochanek K, Jansen-Dürr P, et al. p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 2006; 5(5): 379-89.
  11. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J, et al. p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011; 30(18): 2087-97.
  12. Arima Y, Hayashi N, Hayashi H, Sasaki M, Kai K, Sugihara E, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 2012; 130(11): 2568-79.
  13. Golmohammadi R, Elyasi H, Golmohammadi M. Relationship between P16 Expression and Breast Cancer Using Histology and Immunohistochemistry. J Mazandaran Univ Med Sci 2017; 27(149): 181-6. [Article in Farsi]
  14. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999; 5(2): 243-50.
  15. Brambilla E, Moro D, Gazzeri S, Brambilla C. Alterations of expression of Rb, p16INK4A and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188(4): 351-60.
  16. Ayhan S, Isisag A, Saruc M, Nese N, Demir MA, Kucukmetin NT. The role of pRB, p16 and cyclin D1 in colonic carcinogenesis. Hepatogastroenterology 2010; 57(98): 251-6.
  17. Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A, et al. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res 2008; 28(5A): 2535-9.
  18. Buajeeb W, Poomsawat S, Punyasingh J, Sanguansin S. Expression of p16 in oral cancer and premalignant lesions. J Oral Pathol Med 2009; 38(1): 104-8.
 
  1. Zhao P, Mao X, Talbot IC. Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World journal of gastroenterology: World J Gastroenterol 2006; 12(39): 6391-6.
  2. Horrée N, van Diest PJ, Sie-Go DM, Heintz AP. The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol 2007; 38(8): 1232-8.
  3. Svensson S, Nilsson K, Ringberg A, Landberg G. Invade or proliferate? Two contrasting events in malignant behavior governed by p16INK4a and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 2003; 63(8): 1737-42.
  4. Natarajan E, Saeb M, Crum CP, Woo SB, McKee PH, Rheinwald JG. Co-expression of p16 INK4A and laminin 5 γ2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am J Pathol 2003; 163(2): 477-91.
  5. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002; 160(5): 1573-81.
  6. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, et al. Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 2006; 103(15): 5947-52.
  7. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001; 84(2): 253-62.
  8. Minami R, Muta K, Umemura T, Motomura S, Abe Y, Nishimura J, et al. p16 INK4a induces differentiation and apoptosis in erythroid lineage cells. Exp Hematol 2003; 31(5): 355-62.
 
 
 
 
 
 


 
 
 
 
Sci J Iran Blood Transfus Organ 2018; 15(3): 226-234
Original Article
 

 

The evaluation of P16 in chronic myeloid leukemia
patients
 
 
Barazandeh-Rokh M.1, Nasoohi N.1, Molaei M.2, Fallah P.2
 
 
1Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University (IAUPS), Tehran, Iran
2Allied-Health Faculty, Alborz University of Medical Sciences, Karaj, Iran
 
 
Abstract
Background and Objectives
Chronic Myeloid Leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by the BCR-ABL receptor tyrosinkinase. The tumour suppressor gene of  P16 plays the key role in the cell cycle control. The inactivation of this gene is associated with tumorgenesis, pathogenesis and progression of leukemia. The aim of this study was to evaluate the expression of P16 gene in patients with chronic myeloid leukemia for the identification of the gene expression changes so that the role of the gene in diagnosis and treatment of the disease could be determined.
Materials and Methods
In this descriptive study, the expression of P16 gene in 40 CML patients in chronic phase and 8 healthy subjects as the control all in Payvand Medical Laboratory was examined by Real Time PCR technique. Results were analyzed using the Relative Expression Software Tool (REST2009).
 
Results
P16 gene expression was significantly down-regulated in 32 patients (p ≤ 0.05), and up-regulated in 8 patients (p ≤ 0.05) compared to the control group.
 
Conclusions 
In conclusion, downregulation or upregulation of P16 may be of importance in the biology of CML.Other studies are also required to elucidate the exact function of this tumor suppressor in cancer.
 
Key words: Myeloid Leukemia، Chronic, PCR, Hematopoietic Stem Cells
 
 
 
 
 
 
 
Received:    1 Sep  2017
Accepted: 20 May 2018
 
 

Correspondence: Fallah P., PhD of Hematology & Blood Banking. Allied-Health Faculty, Alborz University of Medical Sciences.
Postal Code: 3147734568, Karaj, Iran. Tel: (+9826) 34349800; Fax: (+9826) 34349802
E-mail:

parvizfallah@gmail.com
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Barazandeh-Rokh M, Nasoohi N, Molaei M, Fallah P. The evaluation of P16 in chronic myeloid leukemia patients. Sci J Iran Blood Transfus Organ 2018; 15 (3) :226-234
URL: http://bloodjournal.ir/article-1-1145-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 15, Issue 3 (Autumn 2018) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.06 seconds with 39 queries by YEKTAWEB 4645